Deanxit
ApprovedSmall molecule
Deanxit is one of 66 small molecule programs targeting Dyspepsia. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
65
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
99 competitors in Dyspepsia
#DrugCompanyPhaseTrials
1Lexapro
AbbViePhase 3
Tofranil
SanofiPhase 3
Elavil
AstraZenecaPhase 3
Pamelor
SSpecgx
Phase 3
Neurontin
VViatris Specialty LLC
Phase 3
Domperidone
Johnson & JohnsonPhase 3
Xifaxan
SSalix
Phase 2
Deanxit
RRenJi Hospital
Approved
Nereus
VVanda Pharmaceuticals
Phase 2
Aciphex
Akero TherapeuticsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Deanxit. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- RRenJi Hospital